Vontobel Holding’s Denali Therapeutics DNLI Stock Holding History

Vontobel Holding’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-17,988	Closed	-$810K	–	1073
2021 Q4	$810K	Buy	17,988 +3,988	+28%	+$189K	0.01%	686
2021 Q3	$706K	Sell	14,000 -254	-2%	-$14.3K	0.01%	699
2021 Q2	$1.12M	Buy	14,254 +254	+2%	+$15.7K	0.01%	567
2021 Q1	$799K	Hold	14,000	–	–	0.01%	569
2020 Q4	$1.08M	Buy	+14,000	New	+$846K	0.01%	520

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Vontobel Holding's DNLI Position: Q1 2022 in Review

Vontobel Holding sold out of Denali Therapeutics (DNLI) in Q1 2022, closing a stake of 17,988 shares — an estimated $810K sold.

Vontobel Holding first reported a position in DNLI in Q4 2020 and held it in 5 quarters. The position peaked at $1.12M in Q2 2021. 190 funds tracked by Wall St. Rank hold DNLI as of Q1 2022.

Vontobel Holding reported no remaining Denali Therapeutics position as of Q1 2022 after selling out during the quarter.
Vontobel Holding sold 17,988 Denali Therapeutics shares in Q1 2022, an estimated $810K.
Vontobel Holding first reported a position in Denali Therapeutics in Q4 2020 and held it in 5 quarters.
Vontobel Holding's Denali Therapeutics position peaked at $1.12M in Q2 2021.
190 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2022.

Based on Vontobel Holding's 13F filing for Q1 2022, filed 13 May 2022.